• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Enovis™ Introduces the Next Generation of Foot and Ankle Surgery Offerings at AOFAS Annual Meeting

    9/5/24 8:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email

    Wilmington, DE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology company, announced today it will unveil its new Tarsoplasty Percutaneous Lapidus System and offer live demonstrations of Better Step, a patient-focused platform, alongside other advanced product offerings at the American Orthopaedic Foot & Ankle Society® (AOFAS) annual meeting in Vancouver, British Columbia from September 11–14, 2024.

     "Our expanding portfolio continues to deliver solutions that drive better patient outcomes and surgical efficiency," said Gary Justak, President and General Manager of Enovis Foot & Ankle. "This year, we're reinforcing that Enovis is not just keeping pace with the rapidly evolving foot and ankle landscape—we're driving it into the fast lane."

    At the meeting, Enovis will unveil the Tarsoplasty Percutaneous Lapidus System, an innovative approach to the Lapidus bunionectomy that features next generation instruments and implants for a more guided, reproducible percutaneous procedure—enabling surgeons to reduce operative time and improve recovery outcomes for patients.

    "The clinical data supporting the Tarsoplasty System highlights the effectiveness of the percutaneous approach to hallux valgus correction," stated Shannon Cummings, Global Vice President of Marketing for Enovis Foot & Ankle. "We're confident that this system will showcase our expertise in percutaneous foot and ankle surgery and our dedication to enhancing these procedures broadly."

    In addition to the Tarsoplasty System, Enovis will offer live demonstrations of Better Step, a patient-focused platform designed to enhance the patient experience throughout the bunion surgery journey. The app encourages physicians to deliver personalized care through custom videos, educational materials, and recovery protocols tailored to each patient's needs.

    "We are thrilled to showcase Tarsoplasty and Better Step at AOFAS," said Justak. "These offerings exemplify our commitment to empowering surgeons and enabling patients to take an active role in their recovery journey."

    The company will also showcase an array of advanced solutions from its comprehensive foot and ankle continuum, including:

    • DynaNail® TTC – TTC Fusion System
    • Evolve34™ – Lapidus Correction System
    • Arsenal Foot Plating System – (Now featuring expanded plating options and Type II anodized titanium alloy).
    • Tiger Cannulated Screw System – (Now featuring a new hexalobe screw head design).
    • DonJoy® Velocity® + Ankle Brace – Ankle Brace
    • Aircast AirSelect Elite – Pneumatic Walking Boot

    AOFAS attendees have opportunities throughout the week to experience these product offerings firsthand.

    • Visit Enovis booth #104 in the exhibit hall.
    • Educational presentations from Drs. Samuel Adams and Christopher Gross on demand virtually, "The Use of Highly Variable Angle Screws increased Compression in Orthopaedic Plating" and in-person on Sept. 12 at 1:30 PM: "Biomechanical Advantages of sustained Dynamic compression over static Fixation in Subtalar Arthrodesis."

    About Enovis

    Enovis™ (NYSE:ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the company's extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.

    Media Contacts

    Diana Aldermae, Enovis™ Foot & Ankle

    [email protected]

    Leda Buster, Enovis™ Bracing & Supports

    [email protected]



    Attachment

    • Enovis Foot & Ankle


    Primary Logo

    Get the next $ENOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    1/6/2026$41.00Buy
    BTIG Research
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    More analyst ratings

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

    Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter 2025 Financial Results Enovis' fo

    2/26/26 6:33:37 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Fourth Quarter and Full Year 2025 Results

    Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter 2025 Financial Results Enovis' fo

    2/26/26 6:10:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

    Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. About Enovis Enovis™ (NYSE:ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for su

    2/3/26 8:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ortiz Christine

    4 - Enovis CORP (0001420800) (Issuer)

    4/2/26 9:00:04 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Administrative Officer Engert Oliver bought $23,740 worth of shares (1,000 units at $23.74), increasing direct ownership by 2% to 48,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    3/16/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Administrative Officer Engert Oliver bought $23,930 worth of shares (1,000 units at $23.93), increasing direct ownership by 2% to 47,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    3/12/26 7:35:49 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Enovis Corporation with a new price target

    BTIG Research initiated coverage of Enovis Corporation with a rating of Buy and set a new price target of $41.00

    1/6/26 8:55:57 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    JMP Securities initiated coverage on Enovis Corporation with a new price target

    JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

    10/3/24 7:29:21 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    JP Morgan initiated coverage on Enovis Corporation with a new price target

    JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00

    6/13/24 7:06:52 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Enovis Corporation

    SCHEDULE 13G/A - Enovis CORP (0001420800) (Subject)

    3/26/26 6:21:49 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by Enovis Corporation

    10-K - Enovis CORP (0001420800) (Filer)

    2/26/26 4:51:18 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Enovis CORP (0001420800) (Filer)

    2/26/26 6:22:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Administrative Officer Engert Oliver bought $23,740 worth of shares (1,000 units at $23.74), increasing direct ownership by 2% to 48,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    3/16/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Administrative Officer Engert Oliver bought $23,930 worth of shares (1,000 units at $23.93), increasing direct ownership by 2% to 47,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    3/12/26 7:35:49 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Administrative Officer Engert Oliver bought $31,045 worth of shares (1,250 units at $24.84), increasing direct ownership by 3% to 44,890 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    3/5/26 8:00:05 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Financials

    Live finance-specific insights

    View All

    Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

    Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter 2025 Financial Results Enovis' fo

    2/26/26 6:33:37 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Fourth Quarter and Full Year 2025 Results

    Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter 2025 Financial Results Enovis' fo

    2/26/26 6:10:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th

    Dallas, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2025 financial results on Thursday, February 26th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, pleas

    1/23/26 8:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    View All

    Enovis Appoints Oliver Engert as Chief Administrative Officer

    Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today. In this newly-created role, Oliver will be responsible for leading Enovis' strategy development, driving organizational efficiency and enhancing operational excellence to support the company in its next phase of profitable, capital-efficient growth. Damien McDonald, CEO of Enovis said, "Oliver's appointment comes at a very exciting time for Enovis. As we take steps to build on our strong foundation and unlock our future potential, his extensive knowledge, skills a

    1/5/26 4:15:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

    Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

    4/2/25 6:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

    NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

    1/7/25 6:19:00 PM ET
    $ARCH
    $CART
    $CEIX
    Coal Mining
    Energy
    Real Estate
    Industrial Specialties

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enovis Corporation

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    11/14/24 1:28:31 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    4/5/24 12:21:51 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    2/14/24 10:04:36 AM ET
    $ENOV
    Industrial Specialties
    Health Care